7,000-plex SomaScan Assay and SomaScan data will be made available to clients by Biostar Technology Limited, according to a recent announcement by SomaLogic, Inc., a pioneer in proteomics technology.
“We are delighted to be partnering with SomaLogic to expand the company’s global reach in Asia by providing their next-generation proteomics offering and establishing the first SomaLogic authorized site in Shanghai,” said founding Chief Executive Officer of Biostar and AccuraMed Steven Qiu. “We believe this partnership with SomaLogic will enable customers in China to make use of the SomaScan Assay as a powerful tool to study the mechanisms underlying the physiological and pathological processes in disease areas like cardiovascular and liver diseases, cancer and diabetes.”
In China, where the company has more than 1,000 clients in academic research, biopharma, clinical translational, and in vitro diagnostics, Biostar Technology Limited was founded in 2006 and has become a major technology supplier in the life sciences and translational medical fields. The nation's first provider of SomaLogic's proteomics technology will now be Biostar.
“China is an exciting market for proteomics with tremendous untapped growth potential for SomaLogic,” said SomaLogic Chief Executive Officer Adam Taich. “Researchers in China have long embraced the value of market leading technology and having Biostar Technology Limited as a trusted partner and authorized site for SomaLogic’s SomaScan Platform will now bring the power of our solution to this region.”
As a third SomaLogic authorised site in the APAC area, Biostar joins Molecular Genomics in Singapore and FonesLife in Japan. Earlier this year, Group 42 Healthcare became the first SomaLogic authorised facility in the Middle East.